• Exicure entered a co-development agreement with Korea-based Adbiotech to evaluate combination therapies using Burixafor (GPC-100).
• Collaboration targets sickle cell disease, acute myeloid leukemia, solid tumors.
• Adbiotech will run in vivo studies, support preclinical validation, translational research.
• Exicure will supply Burixafor, lead clinical and regulatory strategy.
• Parties may advance selected programs into IND-enabling studies, clinical trials, subject to a subsequent definitive agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exicure Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604221954PRIMZONEFULLFEED9695442) on April 22, 2026, and is solely responsible for the information contained therein.